RICHMOND, Va. / Jun 22, 2023 / Business Wire / Owens & Minor, Inc. (NYSE: OMI), a global healthcare solutions company that incorporates product manufacturing, distribution support and innovative technology services, announced today that Ed Pesicka, the Company’s President and CEO, and Jonathan Leon, the Company’s SVP, Corporate Treasurer, will be hosting one-on-one meetings with investors at the UBS Healthcare Services Conference in Chatham, Massachusetts on Tuesday, June 27, 2023.
About Owens & Minor
Owens & Minor, Inc. (NYSE: OMI) is a Fortune 500 global healthcare solutions company integrating product manufacturing and delivery, home health supply and perioperative services to support care through the hospital and into the home. Owens & Minor drives visibility, control and efficiency for patients, providers, and healthcare professionals across the supply chain with proprietary technology and solutions, an extensive product portfolio, an Americas-based manufacturing footprint for personal protective equipment (PPE) and surgical products, as well as a robust portfolio of products and services for patients managing chronic and acute conditions in the home setting. Operating continuously since 1882 from its headquarters in Richmond, Va., Owens & Minor is a 140-year-old company powered by more than 20,000 global teammates. Learn more at https://www.owens-minor.com, follow @Owens_Minor on Twitter and connect on LinkedIn at www.linkedin.com/company/owens-&-minor.
Last Trade: | US$12.55 |
Daily Change: | -0.01 -0.08 |
Daily Volume: | 126,667 |
Market Cap: | US$967.730M |
December 02, 2024 November 04, 2024 September 10, 2024 September 09, 2024 August 02, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB